JVM
Financials
Valuation Metrics
JVM's Market Cap is ₩2835B. At end of 2025 it was ₩3125B. Ranked #637 of 2,405 in KR market (top 26%), #267 of 1,627 on KOSDAQ (top 16%), #108 of 361 in Capital Goods (top 30%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 283.51B KRW | KR#637/2,405 Sec#108/361 |
| Revenue | 177.56B KRW | KR#1,096/2,405 Sec#189/361 |
| Net Income | 30.85B KRW | KR#553/2,405 Sec#104/361 |
| Total Assets | 336.65B KRW | KR#974/2,405 Sec#167/361 |
| Net Assets | 245.83B KRW | KR#833/2,405 Sec#146/361 |
| Employees | 317 | KR#758/2,405 Sec#137/361 |
| Value | ||
| P/E | 9.19x | KR#808/2,405 Sec#118/361 |
| P/B | 1.15x | KR#1,640/2,405 Sec#239/361 |
| P/S | 1.60x | KR#1,732/2,405 Sec#259/361 |
| EV/EBITDA | 8.34x | KR#546/2,405 Sec#79/361 |
| FCF Yield | 10.05% | KR#635/2,405 Sec#105/361 |
| Profitability | ||
| ROE | 12.55% | KR#439/2,405 Sec#76/361 |
| ROA | 9.16% | KR#332/2,405 Sec#50/361 |
| Op. Margin | 20.46% | KR#156/2,405 Sec#21/361 |
| Revenue Growth | 3.30% | KR#1,298/2,405 Sec#184/361 |
| Earnings Growth | -1.19% | KR#838/2,405 Sec#131/361 |
| Financial Health | ||
| Debt Ratio | 36.94% | KR#725/2,405 Sec#86/361 |
| Total Debt | 34.87B KRW | KR#1,152/2,405 Sec#204/361 |
| FCF | 28.49B KRW | KR#428/2,405 Sec#83/361 |
| Cash | 15.44B KRW | KR#1,409/2,405 Sec#232/361 |
| Current Ratio | 2.72x | KR#621/2,405 Sec#63/361 |
| Net Debt/EBITDA | 0.54x | KR#680/2,405 Sec#85/361 |
| Dividend | ||
| Div. Yield | 2.75% | KR#754/2,405 Sec#103/361 |
| Div. Growth | 30.00% | KR#364/2,405 Sec#74/361 |
| Performance | ||
| 1Y Return | -16.10% | KR#1,058/2,405 Sec#158/361 |
| 1M Return | -4.09% | KR#623/2,405 Sec#63/361 |
| From 52W High | -28.72% | KR#381/2,405 Sec#30/361 |
| 1Y MDD | -38.18% | KR#499/2,405 Sec#57/361 |
| Trading | ||
| Volume | 16,869 shares | KR#1,594/2,405 Sec#270/361 |
| Trading Value | 397.2M KRW | KR#875/2,405 Sec#169/361 |
| Foreign Own. | 19.85% | KR#230/2,405 Sec#42/361 |
| Per Share | ||
| EPS | 2,551 KRW | KR#389/2,405 Sec#68/361 |
| BPS | 20,334 KRW | KR#534/2,405 Sec#95/361 |
Company Info
JVM, established in 1977 for equipment development, production, and sales, was listed on KOSDAQ in 2006 and became a subsidiary of Hanmi Pharmaceutical Group in 2016. The company researches, develops, produces, and sells hospital and pharmacy automation systems and related software using its proprietary technology, boasting a diverse product lineup. JVM focuses on R&D and production of next-generation products, supplying equipment to 60 countries through global partners to expand its market presence. It is headquartered in Dalseo-gu, Daegu Metropolitan City.